Qiagen (NYSE:QGEN) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Qiagen (NYSE:QGEN) have received a consensus rating of “Moderate Buy” from the ten research firms that are currently covering the stock, Marketbeat reports. Four equities research analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $50.88.

A number of brokerages have issued reports on QGEN. Hsbc Global Res raised Qiagen to a “hold” rating in a research note on Thursday, October 17th. HSBC cut shares of Qiagen from a “buy” rating to a “hold” rating and set a $49.00 price target on the stock. in a research report on Thursday, October 17th. Finally, Robert W. Baird raised their price objective on shares of Qiagen from $49.00 to $52.00 and gave the company an “outperform” rating in a research report on Friday, August 2nd.

Qiagen Price Performance

Shares of NYSE:QGEN opened at $42.78 on Wednesday. Qiagen has a 52 week low of $39.03 and a 52 week high of $47.44. The firm has a market capitalization of $9.76 billion, a P/E ratio of 109.69, a PEG ratio of 3.28 and a beta of 0.41. The firm’s 50 day moving average is $43.43 and its two-hundred day moving average is $43.73. The company has a current ratio of 2.17, a quick ratio of 1.89 and a debt-to-equity ratio of 0.39.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. GAMMA Investing LLC raised its position in Qiagen by 806.5% during the third quarter. GAMMA Investing LLC now owns 562 shares of the company’s stock valued at $26,000 after acquiring an additional 500 shares in the last quarter. Toronto Dominion Bank acquired a new stake in Qiagen during the second quarter worth $27,000. Massmutual Trust Co. FSB ADV increased its stake in Qiagen by 39.8% in the third quarter. Massmutual Trust Co. FSB ADV now owns 853 shares of the company’s stock valued at $39,000 after acquiring an additional 243 shares during the period. CWM LLC raised its holdings in shares of Qiagen by 12.0% in the 2nd quarter. CWM LLC now owns 2,505 shares of the company’s stock worth $103,000 after buying an additional 269 shares in the last quarter. Finally, Headlands Technologies LLC boosted its stake in shares of Qiagen by 396.6% in the 2nd quarter. Headlands Technologies LLC now owns 2,741 shares of the company’s stock valued at $113,000 after purchasing an additional 2,189 shares in the last quarter. Hedge funds and other institutional investors own 70.00% of the company’s stock.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.